Clinical and Experimental Department of Medicine and Pharmacology, University of Messina, Italy.
Cardiologia Nuovo Presidio Ospedaliero Cutroni Zodda-Barcellona P.d.G (Me) AUSL5 Messina, Italy.
Int J Cardiol. 2010 Nov 19;145(2):e77-e79. doi: 10.1016/j.ijcard.2009.03.131. Epub 2009 Apr 28.
Previous studies have suggested that subclinical thyroid dysfunction is associated with detrimental effects on the cardiovascular system. Subclinical hyperthyroidism is an increasingly recognized entity that is defined as a normal serum free thyroxine and free triiodothyronine levels with a TSH level suppressed below the normal range and usually undetectable. It has been reported that subclinical hyperthyroidism is not associated with coronary heart disease or mortality from cardiovascular causes but it is sufficient to induce arrhythmias including atrial fibrillation and atrial flutter. It has also been reported that increased factor X activity in patients with subclinical hyperthyroidism represents a potential hypercoagulable state. Subclinical hypothyroidism is defined by elevated serum levels of TSH with normal levels of free thyroid hormones. Subclinical hypothyroidism is characterized by abnormal lipid metabolism, cardiac dysfunction, diastolic hypertension conferring an elevated risk of atherosclerosis, and ischemic heart disease. It has been reported that sub-clinical hypothyroidism is associated with both, a significant risk of coronary heart disease at baseline and at follow-up and that mortality from cardiovascular causes is significantly higher at follow-up. However subclinical thyroid dysfunction is currently the subject of numerous studies and remains controversial, particularly as it relates to cardiovascular morbidity and mortality and clinical applications. Pericardial effusion can be present in systemic disorders including hypothyroidism and subclinical hypothyroidism too. Pericardial effusion is extremely rare as an expression of hyperthyroidism. We present a case of pericardial effusion associated with a subclinical hyperthyroidism during the hyperthyroid phase of the chronic autoimmune thyreopathy (Hashitoxicosis).
先前的研究表明,亚临床甲状腺功能障碍与心血管系统的不良影响有关。亚临床甲状腺功能亢进症是一种日益被认识到的病症,其定义为血清游离甲状腺素和游离三碘甲状腺原氨酸水平正常,促甲状腺激素(TSH)水平低于正常范围且通常不可检测。据报道,亚临床甲状腺功能亢进症与冠心病或心血管原因导致的死亡率无关,但足以引起心律失常,包括心房颤动和心房扑动。也有报道称,亚临床甲状腺功能亢进症患者的因子 X 活性增加代表潜在的高凝状态。亚临床甲状腺功能减退症的定义是血清 TSH 水平升高,游离甲状腺激素水平正常。亚临床甲状腺功能减退症的特征是异常的脂质代谢、心脏功能障碍、舒张期高血压,增加了动脉粥样硬化和缺血性心脏病的风险。据报道,亚临床甲状腺功能减退症与冠心病的基线和随访风险显著增加以及随访期间心血管原因导致的死亡率显著增加有关。然而,亚临床甲状腺功能障碍目前是许多研究的主题,仍然存在争议,特别是在涉及心血管发病率和死亡率以及临床应用方面。心包积液也可能存在于包括甲状腺功能减退症和亚临床甲状腺功能减退症在内的全身性疾病中。心包积液在甲状腺功能亢进症中极为罕见。我们报告了一例在慢性自身免疫性甲状腺疾病(桥本甲状腺毒症)的甲状腺功能亢进期发生的与亚临床甲状腺功能亢进症相关的心包积液病例。